Literature DB >> 8560539

Acquired antibody levels to Plasmodium falciparum merozoite surface antigen 1 in residents of a highly endemic area of Papua New Guinea.

F al-Yaman1, B Genton, K J Kramer, J Taraika, S P Chang, G S Hui, M P Alpers.   

Abstract

The prevalence and concentration of antibodies to a yeast-expressed N-terminal region (195A) and a baculo-virus-expressed C-terminal region (BVp42) of merozoite surface antigen 1 (MSA-1) were measured during a cross-sectional survey in the Wosera area of East Sepik Province, Papua New Guinea, in order to obtain baseline data on naturally acquired antibody response to this antigen in preparation for a vaccine trial. Overall, the seropositivity rate was 78% for 195A and 91% for BVp42. Although antibody prevalence to both molecules increased with age, higher antibody prevalence rates were observed for BVp42 in all age groups studied. In children, significant positive associations were found between parasite prevalence and antibody prevalence for both regions of MSA-1 and between spleen rates and anti-BVp42 antibody prevalence. Concentration of antibody against both regions increased significantly with age, but was always higher for BVp42. In children, antibody levels to both regions of MSA-1 were significantly higher in those infected (symptomatic and asymptomatic), while in adults no significant difference in antibody concentration was observed between those infected and those uninfected. However, enlarged spleens were associated with higher antibody concentration to both regions of MSA-1 in both children and adults. The C-terminal of MSA-1 appeared to be more recognized than the N-terminal, in terms of both antibody prevalence and concentration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8560539     DOI: 10.1016/0035-9203(95)90106-x

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  6 in total

1.  Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria.

Authors:  I S Soares; G Levitus; J M Souza; H A Del Portillo; M M Rodrigues
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

Review 2.  Malaria tolerance--for whom the cell tolls?

Authors:  Craig S Boutlis; Tsin W Yeo; Nicholas M Anstey
Journal:  Trends Parasitol       Date:  2006-06-19

3.  Comparison of diagnostic methods for the detection and quantification of the four sympatric Plasmodium species in field samples from Papua New Guinea.

Authors:  Anna Rosanas-Urgell; Dania Mueller; Inoni Betuela; Céline Barnadas; Jonah Iga; Peter A Zimmerman; Hernando A del Portillo; Peter Siba; Ivo Mueller; Ingrid Felger
Journal:  Malar J       Date:  2010-12-14       Impact factor: 2.979

4.  How Should Antibodies against P. falciparum Merozoite Antigens Be Measured?

Authors:  Sriwipa Chuangchaiya; Kristina E M Persson
Journal:  J Trop Med       Date:  2013-04-18

5.  Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.

Authors:  Bernhards R Ogutu; Odika J Apollo; Denise McKinney; Willis Okoth; Joram Siangla; Filip Dubovsky; Kathryn Tucker; John N Waitumbi; Carter Diggs; Janet Wittes; Elissa Malkin; Amanda Leach; Lorraine A Soisson; Jessica B Milman; Lucas Otieno; Carolyn A Holland; Mark Polhemus; Shon A Remich; Christian F Ockenhouse; Joe Cohen; W Ripley Ballou; Samuel K Martin; Evelina Angov; V Ann Stewart; Jeffrey A Lyon; D Gray Heppner; Mark R Withers
Journal:  PLoS One       Date:  2009-03-05       Impact factor: 3.240

6.  IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life.

Authors:  Samson M Kinyanjui; David J Conway; David E Lanar; Kevin Marsh
Journal:  Malar J       Date:  2007-06-28       Impact factor: 2.979

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.